Global Anti Infectives Market Size By Type (Antibacterial, Antiviral), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Anti-Infectives Market was valued at USD 92.4 billion in 2023 and is projected to surpass USD 134.1 billion by 2031, growing at a CAGR of 4.8% during the forecast period from 2023 to 2031. Anti-infectives, which include antibiotics, antivirals, antifungals, and antiparasitics, are critical in the prevention and treatment of infectious diseases. The market is witnessing significant growth due to the increasing incidence of infections worldwide, rising antimicrobial resistance (AMR), and the introduction of novel therapies. Public health initiatives, advancements in drug discovery, and an increase in global disease surveillance also support market expansion.

Drivers:

1. Rising Incidence of Infectious Diseases:

Emerging and re-emerging infectious diseases such as COVID-19, influenza, tuberculosis, and hepatitis are driving the demand for anti-infective drugs worldwide.

2. Antimicrobial Resistance (AMR):

Growing antimicrobial resistance is compelling governments and pharmaceutical companies to invest in novel anti-infective agents, fostering research and development in this sector.

3. Government and Global Health Initiatives:

Organizations like WHO and CDC, along with national governments, are implementing policies and funding programs to combat infectious diseases, encouraging market growth.

4. Increasing Geriatric and Immunocompromised Population:

Aging populations and individuals with weakened immune systems are more susceptible to infections, thereby driving the demand for anti-infective therapies.

Restraints:

1. Stringent Regulatory Environment:

The development and approval of anti-infectives are tightly regulated, often delaying time-to-market for new products.

2. Patent Expirations and Generic Competition:

The expiration of patents for blockbuster drugs invites generic competition, which can negatively impact revenue for originator companies.

Opportunity:

1. Development of Novel Drug Classes and Combinations:

Innovation in anti-infective formulations, including combination therapies, presents opportunities to combat resistant strains and expand treatment options.

2. Untapped Markets in Low- and Middle-Income Countries:

Expanding access to diagnostics and treatments in emerging economies presents vast growth potential, particularly where infectious diseases are endemic.

3. Biotech Collaborations and Strategic Alliances:

Collaborative efforts between big pharma and biotech firms are accelerating the pipeline of next-generation anti-infectives.

Market by System Type Insights:

The Antibiotics segment held the largest market share in 2023, due to its wide applicability in treating bacterial infections. Despite resistance challenges, antibiotics remain a cornerstone of anti-infective therapy. The Antivirals segment is expected to witness the fastest growth, supported by increasing cases of viral infections and investments in antiviral drug development, especially in the wake of pandemics and hepatitis management.

Market by End-use Insights:

The Hospital Pharmacies segment dominated the market in 2023, as hospitals are primary centers for treating severe infections requiring prescription-based anti-infectives. The Retail Pharmacies segment is also gaining traction, driven by the rising number of outpatient prescriptions for mild infections.

Market by Regional Insights:

North America led the market in 2023, supported by strong healthcare infrastructure, high awareness levels, and the presence of leading pharmaceutical players. Asia-Pacific is projected to experience the fastest growth during the forecast period, driven by increasing healthcare access, rising infection rates, and strong government initiatives in countries like India and China.

Competitive Scenario:

Prominent players in the Global Anti-Infectives Market include Pfizer Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Gilead Sciences, Inc., Roche Holding AG, Sanofi, AbbVie Inc., Astellas Pharma Inc., and Novartis AG. These companies are focused on strategic partnerships, acquisitions, and the development of broad-spectrum anti-infectives.

Key Market Developments:

In 2024, Gilead Sciences expanded its antiviral pipeline through the acquisition of a biotech firm specializing in RNA-targeting antivirals.

Pfizer Inc. announced successful Phase III results for a novel oral antibiotic targeting multi-drug-resistant bacterial strains.

Sanofi collaborated with a government-backed consortium to enhance antibiotic development against AMR pathogens in underserved markets.

Scope of Work – Global Anti-Infectives Market

FAQs:

1) What is the current market size of the Global Anti-Infectives Market?

The market was valued at USD 92.4 billion in 2023.

2) What is the major growth driver of the Global Anti-Infectives Market?

The increasing incidence of infectious diseases and rising antimicrobial resistance are key growth drivers.

3) Which is the largest region during the forecast period in the Global Anti-Infectives Market?

North America held the largest market share in 2023.

4) Which segment accounted for the largest market share in the Global Anti-Infectives Market?

The Antibiotics segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Anti-Infectives Market?

Major players include Pfizer, GSK, Merck, Johnson & Johnson, Gilead, Roche, Sanofi, AbbVie, Astellas, and Novartis.